Tivozanib Matches Nexavar on Cancer Survival Rate

Astellas and Aveo Pharmaceuticals have announced that the overall survival (OS) data for their kidney cancer drug, tivozanib, which demonstrates that it matches a key competitor. Two-year data from the TIVO-1 clinical study shows that there is no statistically significant difference in the overall survival rate for tivozanib and Bayer/Onyx’s Nexavar, with both treatments providing

Continue Reading

Sanofi Earnings Knocked by Generics

Sanofi’s fourth quarter earnings have been hit by generics, although the majority of the patent cliff is now behind the French drugmaker, who anticipate a return to growth in the second half of 2013. Business net income, which excludes items, dropped 27.1% to 1.57 billion euros (at constant exchange rates), mainly as a result of

Continue Reading

Takeda Posts Q3 Financials, Boosted by Nesina and Pantoprazole Sales

Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (around $1.51 billion), however sales increased by 5.5% to 1.189 trillion yen.  Actos

Continue Reading

Watson Pharmaceuticals Renamed to Actavis and Announce Growth Strategy

Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding campaign that will guide the transition of their facilities, operations and commercial

Continue Reading

Scotland Unveils £21m Fund for Rare Diseases

A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014.  It will help cover successful new Individual Patient Treatment Requests for drugs that target rare

Continue Reading

Amgen Partners with BIND in $180 Million Agreement

Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therapeutics,” which they call Accurins.  The partners are planning

Continue Reading

Ulcerative Colitis Drug Market to Reach $3.7 Billion by 2021

Sales of medication to treat ulcerative colitis in seven key markets are expected to double over the next decade, reaching $3.7 billion by 2021, according new research. The rapid growth will be largely driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors – Abbott/Eisai’s Humira and Janssen/Merck/Mitsubishi Tanabe’s Simponi – and two novel therapies –

Continue Reading